NWRD 08
Alternative Names: NWRD-08Latest Information Update: 28 Feb 2024
At a glance
- Originator Newish Technology (Beijing)
- Class DNA vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Human papillomavirus infections
Most Recent Events
- 25 Jan 2024 Phase-I clinical trials in Human papillomavirus infections in China (IM) (NCT06276101)
- 24 Jul 2023 National Food and Drug Administration (NMPA) approves IND application for NWRD 08 in Human papilloma virus infections
- 24 Jul 2023 Efficacy, adverse events and immunogenicity data from a clinical trial in Human papillomavirus infections released by Newish Technology